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Summary
We analyzed the recently defined ability of CD3-CD16+ cells to specifically recognize and lyse
normal allogeneic target cells (PHAinduced blasts). The susceptibility to lysis by a given alloreactive
natural killer (NK) clone ("1 anti-A") was expressed by PHA blasts derived from 9 of 38 random
donors analyzed. In all instances, the specific lysis of "susceptible" target cells was >35% while
that of "nonsusceptible" targets was <6% at an E/T cell ratio of 5:1. In addition to 1 antiA,
A anti-1 specific CD3-CD16-' clones could also be isolated from the reverse MLC combination.
The relationship existing between lysis of normal allogeneic cells or tumor cells by the same
CD3-CD16+ effector cell has been investigated: 1 anti-A specific CD3-CD16+ clones lysed PHA
blasts of three of six cancer patients, while they lysed fresh tumor cells (ovarian carcinoma) from
all six patients. The type of inheritance of the character "susceptibility to lysis" was analyzed
in representative families. This analysis revealed that the character is inherited in an autosomic
recessive fashion, and it is therefore different from MHC. We further investigated the type of
segregation ofthe opposite character "resistance to lysis" (which is inherited in a dominant mode).
The finding that this character segregated in all donors expressing given MHC haplotypes indicated
that the gene regulating the expression of the NK-defined alloantigen is present on chromosome 6.
N
atural killer cells are known as lymphocytes able to lyse
tumor target cellsthrough a non-MHC-restricted type
of recognition. Since these cells lack both surface Ig and
CD3/TCR molecular complex, it is generally thought that
they are unable to recognize antigens (1, 2). However, recent
findings appear to challenge this concept since CD3-CD16+
peripheral blood-derived NK cells were shownto be capable
ofspecific proliferationin MLC against some allogeneicdonors.
Perhaps more importantly, either populations or clones of
such WC-derived CD3-CD16+ cells specifically lysed normal
allogeneic target cells (PHA-induced blasts) derived from the
stimulating donors (but not autologous target cells) (3). The
aim of the present study was to characterize this novel NK
cell-mediated specificity. We show that the character "sus-
ceptibility to lysis" is present in approximately one-fourth
of random donors having different MHC haplotypes. In ad-
dition, lysis of normal allogeneic cells can be clearly distin-
guished from the conventional non-MHC-restricted lysis of
tumor cells. Genetic analysis shows that the character is in-
herited in an autosomic recessive fashion (thus differing from
MHC) and is carried by chromosome 6.
Materials and Methods
Isolation of CD3-CD16+ Lymphocytes, MLC, Cell Cloning, and
Evaluation ofCytolytic Activity. PBL derived from normal donors
were isolated on Ficoll-Hypaque (F-H)t gradients and cells were
then incubated with a mixture ofanti-CD3 (OKT3, Ortho Phar-
maceuticals, Raritan, NJ), anti-CD4 (HP26), and anti-CD8 (B9.4)
mAbs followed by treatment with rabbit complement for 1 h at
37°C as previously described (3). Viable cells were isolated by F-H
gradients and cultured in microwells (5 x 104 cells/well) in the
presence of allogeneicirradiated mononuclear cells; after 4 d, the
cultures were supplemented with 100 U/ml of rIIr2. The MLC-
derived cells were cloned underlimiting dilution conditions in the
1 Abbreviation used in this paper: F-H, Ficoll Hypaque.
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as described (4-6). 10-20 d later the cytolytic activity was tested
in a 4-h "Cr-release assay, in which effector cells were tested
against PHA blasts derived from different allogeneic (or autolo-
gous) donors. PHAblasts were obtained by culturingPBL for 4 d
with 0.5% PHA (vol/vol) in the presence of rIL2 (100 U/ml).
In some experiments fresh uncultured tumor cells were used as
targets. Target cells were used at 5 x 10'/well, forafinalE/Tcell




105 cells were stained with the
appropriate mAb followed by fluoresceinated goat anti-mouse Ig.
Control aliquots were stained with the fluorescent reagent alone.
All sampleswere then analyzed on aflow cytometer(PACSSTAR,
Becton Dickinson, Mountain View,CA)gatedto excludenonviable
cells. Results areexpressedas arbitrarynormalized fluorescence histo-
grams, i.e., number of cells vs. fluorescence intensity. The mAbs
used in these studies were represented by anti-Leu-4 (anti-CD3,
Becton Dickinson), WT31(directedto theTCRcomplexexpressed
by TCR-a/0-bearing cells; Sanbio, Uden, theNetherlands), BB3
(directedto thedisulphide-linked form of TCR-y/6) (4), 6-TCS-1
(directed to the 6 chain of non-disulphide-linked TCR-y/6) (5),
MAR 206 (anti-CD2) (7), and KDI (anti-CD16) (6).
IsolationofFreshTumorTarget Cells.
￿
Ascitic fluid was collected
by paracentesis from patients with stageIII-IV ovarian carcinoma
into sterile 500-ml bottles contamin~. 5,000U heparin. The pres-
ence ofneoplastic cells was con='by hist6pathologic analysis.
Cells isolated by standard F-H density gradient centrifugation and
macrophages were removedby adherence to plasticflasks at 37°C,
5% C02, for 1 h. Tumor cells were further purified by centrifu-
gation over discontinuous F-H density gradientsas previously de-




PBMC from normal donors were HLA typed
using the standard National Institute of Health (liethesda, MD)
complement-mediated microcytotoxicity assay.
Results and Discussion
Specificity of Alloreactive CD3-CD16+ NK Clones.
￿
Pe-
ripheral CD3-CD16+ lymphocytes derived from individual
1 upon MLC against irradiated allogeneic cells from donor
A ("1 anti-A") were shown to efficiently lyse PHAinduced
blasts derived from donor A (3). To determineto which ex-
tent "1 anti-A" cloned effector cells crossreacted with ran-
domly chosen unrelated donors, they were tested for their
capability oflysing PHAblasts derived from 38 normal indi-
viduals. 9 of 38 were found to be susceptible to lysis: the
degree of cytolysis was consistently high (35-85% specific
lysis at an E/T ratio of 5:1) and comparable to that detected
when target cells from donor A were used. On the other
hand, the levels of specific lysis of "nonsusceptible" donors
did not exceed 6% at the same E/T ratio.
As previously shown(3), upon stimulation in MLC against
donor A, anti-A specific CD3-CD16+ clones can be derived
from a number of responders. In these experiments, anti-
A-specific clones were derived from representative individ-
uals 1, 2, and 3 (resistant to lysis by 1 anti-A clones) and
then tested for their pattern of reactivity against a panel of
PHA blasts derivedfrom donors B, C, D (susceptible to lysis)
or donors 1, 2, 3 (resistant to lysis). It should also be noted
48
￿
Specific Recognition of CD3 -CD16 + Natural Killer Cells
that not all CD3-CD16+ clones derived from a given in-
dividual reacted against A. Thus, in three representative in-
dividuals, the anti-A-specific clones were -11, 18, and 24%
of the total CD3-CD16+ clones analyzed. Table 1 shows that
"antiA" reactive clones derivedfrom individuals 2 and 3 selec-
tively lysedB, C, and D target cells. In addition, an identical
pattern of reactivity was observed with clones that had been
derived from individuals 1, 2, and 3 against donor B (Table
1) . It is important to note that no clones capable of lysing
autologous target cells could be detected either in donors 1,
2, and 3(Table 1), or in donors A andB (not shown). Given
the ability of NK cells of donor 1 to specifically recognize
target cells of donorA, we further investigated whether NK
cells from donor A could lyse target cells of donor 1. Table
2 shows thepatternof reactivity of representative NK clones
generated in the reverse MLC combination (i.e., A anti-1).
It is evident that also A anti-1 clones specifically lysed only
Table 1.
￿
Specificity of WC-Derived CD3-CD16*
' Clones were derived from CD3-CD16 " populations cultured in
MLC against donor A or B, respectively.
t Target cells were represented by PHA-blasts derived from donors
1, 2, 3, A, B, C, D.
S Results are expressed as percent of specific "Cr release at an E/T
ratio of 5:1.
II (1) Clone derived from individual 1; (2) clone derived from in-





3 A B C D
Anti-A
CA 8.25 (1)II 0§ 2 0 67 45 48 66
CA 2.100 (1) 1 0 0 64 36 38 56
CA 6.50 (1) 3 1 1 75 46 58 54
TA 7.50 (2) 2 1 2 39 43 49 45
TA 10.50 (2) 0 3 2 52 40 53 54
TA 2.50 (2) 2 0 0 53 60 47 48
L 41 (3) 0 1 1 54 35 66 63
L 92 (3) 3 2 2 52 70 52 49
Anti-B
E 168 (1)I1 0 0 1 51 62 59 55
G 10 (1) 2 0 0 48 55 56 52
H 12 (1) 2 1 1 61 65 57 49
TG4.25 (2) 0 0 1 65 72 58 61
TG8.50 (2) 2 3 0 49 57 52 47
TG2.50 (2) 2 2 1 45 51 48 52
L 93 (3) 0 0 0 58 75 46 47Table 2.
￿
Specificity of CD3 - CD16' Cytolytic Clones
Derived from the Reverse MLC Combination (A Anti-1)
= Clones were derived from CD3-CD16+ populations from donor A
and cultured in MLC in the presence of irradiated feeder cells from
individual 1.
' Target cells were represented by PHA-blasts derived from donor 1,
2, 3, A, B, C, D.
Results are expressed as percent of specific s'Cr release at an E/T
of 5:1 .
some allogeneic cells; however, theirpattern ofreactivitywas
clearly different from that of 1 anti-A clones.
Lack of CD3-TCR Expression in Alloreactive CD3-16'
Clones Phenotypic analysis of several representative CD3-16'
alloreactive clones showed a lack of reactivity with a panel
of anti-CD3 mAbs or mAbs specific for different types of
N
Z
CONTROL anti-CD2 anti-CD3 WT31
TCR (Fig. 1). In addition, Northern blot analysis did not
show detection of productive mRNA for TCR-a, ß, and
,y chains or for CD3 y and b chains. Conversely, CD3 e
mRNA was consistently present (not shown). These data
are in agreement with our previous reports on cloned NK
cells (3, 9).
NK Cell-mediated Recognition ofNormalAllogeneic CellsCan
Be Distinguishedfrom Lysis of Tumor Cells. We next inves-
tigated the relationship existing between the NK cell-medi-
ated lysis ofnormal allogeneic cells and the conventional non-
MHC-restricted lysis of tumor target cells. To address this
question, we analyzed alloreactive CD3-CD16+ clones for
their cytolysic activity against either PHA blasts or tumor
cells (ascitic ovarian carcinoma cells) isolated from a number
of patients. No preferential lysis was observed against tu-
mor cells isolated from patients whose PHA blasts were
lysed by the alloreactive 1 anti-A clones. Table 3 shows that
CD3-CD16+ clones lysed PHA blasts of 3 of 6 patients
only, while they lysed tumor cells from all patients. In addi-
tion, tumor cells were efficiently lysed also by those
CD3+CD16+ clones (used as control) that did not display
any evident reactivity against normal PHA blasts (derived
from donor A). These results indicate that the specific recog-
nition of normal allogeneic cellsand the MHC-unrestricted
cytolysis oftumor cells represent two independent functional
capabilities of NK cells, possibly related to different mecha-














Lack of T cell markers in alloreactive CD3-CD16' ef ector cells. Surface antigens expressed by a representative
CD3-CD16' polyclonal cell population (lane 1) or by three clones displaying specific cytolytic activity against allogeneic PHA-blasts. (lane 11)
clone G10; (lane Ill) clone H12; (lane IV) clone E168. The mAbs used in these studies were represented by anti-Leu4 (anti-CD3, Becton Dickin-
son and Co.), WT31 (directed to TCR-a/ß; Sambio, Uden, The Netherlands), BB3 (directed to the disulphide-linked form of TCR-y/6) (4),
6-TCSI (directed to the 6 chain of non-disulphide-linked TCRJy/6) (5), MAR 206 (anti-CD2) (7), KDl (anti-CD16) (6).
MLC-activated
10 in 10- m, W1 01 l
"Cr-labeled target cells"




A B C D
AGT llt 34S 25 40 4 4 5 2
AGD 5 44 18 35 4 3 4 0
AGD 17 52 ND 39 0 1 8 4
AGD 27 37 ND 33 0 1 6 7Table 3.
￿
Cytolytic Activity of CD3-CD16+ Clones against Normal PHA Blasts or Tumor Cells Derived from
Individual Cancer Patients
Mode ofInheritance of the Character "Susceptibility to Lysis."
To investigate whether the alloantigen recognized by CD3-
CD16+ cells could be represented by molecules encoded by
class I or class II MHC genes, we determined whether the
character "susceptibility to lysis" was codominantly inherited
(as MHC markers are) (10). To this end, target cells were
derived from parents ofdonors A and B. In these experiments,
the reactivity of alloreactive 1-anti-A or 1-anti-B CD3-CD16+
clones was compared with that of conventional CD3+TCR-
a/o+ alloreactive (anti-A or anti-B) cytolytic clones. As ex-
pected, MY clones lysed at least one of the parent's cells.
In contrast, anti-A- or anti-B-specific CD3-CD16+ clones
failed to lyse target cells derived from any of these parents
(Table 4). These results suggest that, different from HLA,
the character examined is recessively inherited.
To gain more precise information on the mechanism of
inheritance of this genetic trait, we studied a large family
of 38 members spanning three generations (Fig. 2). The PHA
blasts derived from these individuals were analyzed for their
susceptibility to lysis by "1-anti-A" CD3-CD16+ clones. In
this family, the female founder, whose blast cells were sus-
ceptible to lysis, had eight offspring; of these, four (50%)
were susceptible to lysis. Recessivity of the trait "suscepti-
bility to lysis" is shown by its segregation in the second and
thirdgeneration. In fact, crosses between two resistant partners
(see for example 54x78, 65x58, or 85x55) gave rise to sus-
ceptible individuals among the progeny. Furthermore, the
progeny of a susceptible father (73) and of a resistant mother
(52) or, vice versa, of a resistant father (75) and of a sensitive
mother (53), are all resistant to lysis by alloreactive MY
CD16+ cells. Pedigree analysis also shows that the progeny
of partners who were both susceptible to lysis (for example
59x83 or 57x64) are also composed of susceptible individ-
uals (5/5) for each mating. Although lymphocytes from the
"Cr-labeled target cells
All the clones analyzed were derived from individual 1. Clones CA8.25 and CA2.100 had been preselected on the basis of their ability to lyse
donor A ("1 anti-A" specificity), whereas the remaining three did not lyse donor A. Target cells were represented by peripheral blood-derived
PHA-activated lymphocytes, whereas tumor cells were isolated from the ascitic fluid of six patients affected by ovarian carcinoma, as previously
described by Ferrini et al. (8). Note that anti-A-specific clones lysed PHA blasts from donor FR, IA and AD, but not PR, SC and RA,
whereas the remaining clones, used as control, did not lyse PHA blasts derived from any patient. In contrast all clones lysed tumor cells from
all patients, independently on their anti-A specificity. Results are expressed as percent specific s1Cr-release at an E/T ratio of 10:1.
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Table 4.
￿
Cytolytic Activity of Alloreactive CD3-CD16* or
CD3*TCR-ot/#* Clones
Target cells were represented by PHA blasts derived from donors
A and B and from their mothers and fathers.
S (1) Clone derived from individual 1; (2) clone derived from in-
dividual 2; (3) clone derived from individual 3 .
1 Results are expressed as percent specific s1Cr release at an E/T ra-
tio of 5:1.
t CD3+ clones EA2 and EG21 were derived from individual 1 upon
stimulation in NEC against donor A or B, respectively.



























CA8.25 58 39 43 30 46 27 0 50 0 40 0 40
CA2.100 56 26 53 20 52 20 0 30 0 50 0 26
C 42 2 18 0 16 0 16 0 73 4 40 0 65
C 26 0 40 0 25 0 23 0 62 10 75 0 55








CA 8.25 (1)S 671 0 6 45 0 1
CA 2.100 (1) 64 0 3 36 0 2
CA 6.50 (1) 75 5 0 46 1 1
E 168 (1) 51 2 0 62 0 0
* 10 (1) 48 1 2 55 1 0
* 12 (1) 61 3 2 65 0 0
TA 7.50 (2) 39 1 0 43 2 1
TA 10.50 (2) 52 3 1 40 0 2
TA 2.50 (2) 53 0 0 60 2 5
L 41 (3) 54 3 0 35 2 4
L 92 (3) 52 0 0 70 0 0
L 93 (3) 58 2 1 75 0 3
CD3+TCR-ct/a+
clones
EA2 (1) 33 34 0 ND ND ND
EG21 (1) ND ND ND 61 2 45Figure 2 .
￿
Mode of inheritance of the character "susceptibility to lysis" by CD3-CD16' cells in a representative family. Black symbols refer to
(PHA blasts of) individuals susceptible to lysis by "1 anti-A" alloreactive CD3-CD16+ cells, whereas resistance to lysis is represented by open
symbols. Circles are used for female and squares for male donors . Letters within the symbols indicate serologically defined MHC haplotypes in-
cluding markers for the A, B, C, DR, and DQ loci . The effector cells used were represented by MLC-derived CD3-CD16+ polyclonal popula-
tion or clones from individual 1 raised against donor A .
male founder were no longer available for analysis, on the
basis of 50% segregation, it can be inferred that he was het-
erozygous for the locus determining the phenotype exam-
ined (and must thus have been resistant to lysis) . In contrast,
his mate (no. 56) is homozygous for the locus causing sus-
ceptibility. From these observations it is possible to con-
clude that the trait "susceptibility to lysis" by alloreactive
CD3-CD16+ cells is an autosomally inherited recessive
character.
The fact that "susceptibility to lysis" is a recessive character
suggests that the locus governing susceptibility or resistance
to lysis does not encode an alloantigen itself, but rather a
factor that negatively regulates the expression of the alloan-
tigen . According to this hypothesis, the activity of a domi-
nant locus determining the resistance to lysis in a given
individual would inhibit the expression of the putative al-
loantigen (see the heterozygous individuals nos . 52 and 58
and the homozygous nos. 67, 82, or 86) .
Further analysis of the pedigree (Fig . 2) indicates that the
presence ofMHC "a" haplotype (a = A2, B44, Cw4,DQw3)
is always associated with the character "resistance to lysis"
"Resistance to lysis" is also observed in all the individuals
carrying the haplotypes x4, x5, y6, and y8 (Fig. 2) . These
data suggest that the character "resistance to lysis" segregates
in all donors expressing givenMHC haplotypes . As a conse-
quence, the genes that regulate the susceptibility to lysiswould
be present on chromosome 6 .
In conclusion, our present data indicate that CD3-CD16+
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NK lymphocytes are capable of specific recognition and that
the alloantigen recognized is clearly distinguishable fromHLA
antigens as indicated by its mode of inheritance. Suscepti-
bility to NK cells has been reported to correlate with low
expression ofMHC class I antigen on B-EBV-transformed
target cells (11, 12) ; however, in our experiments no differ-
ences in the amounts of HLA class I antigen could be de-
tected onPHAinduced blast cells derived from either sus-
ceptible or resistant individuals. Although in this study we
analyzed the alloantigen defined by 1 anti-A effector cells,
our data indicate that at least a second NK-defined specificity
exists. Thus, in addition to 1 anti-A clones, also alloreactive
specific clones could be generated in the reverseMLC combi-
nation (A anti-1) .
In the mouse, NK cells have been shown to reject H-2-
compatible/Hh1-incompatible bone marrow grafts (the so-
called hybrid resistance phenomenon) (13) . Genes control-
ling the expression of Hh antigens were shown to be trans-
mitted in an autosomal recessive mode and weremapped on
mouse chromosome 17, telomeric to H2-S, and centromeric
to H-2D (14) . In view of the close similarity between these
two phenomena, it is possible that the ability of human
CD3-CD16+ cells to recognize alloantigens may represent
thehuman counterpart ofmurine hybrid resistance (15, 16) .
While cloned NK cells specifically lysed appropriate normal
allogeneic cells (PHA blasts), the lysis of tumor target cells
was clearly unrelated to this phenomenon . It would be im-
portant to define whether this may represent a major func-tion of human NK cells, perhaps physiologically more rele-
vant than the non-MHC-restricted cytolytic activity. The
ability ofNK cellsto recognizealloantigen maynotbe phys-









We thank C. Di Donato for technical help and C. Miriello for secretarial assistance.
This work was partially supported by CNR and AIRC. O. Viale is a recipient of an AIRC fellowship.
Address correspondence to Dr. Lorenzo Moretta, Istituto Nazionaleperla Ricerca sul Canceo, viale Benedetto
XV, n. 10, 16132 Genova, Italy
Received for publication 5January 1990.
Herberman, R. R, and J. R. Ortaldo. 1981. Natural killer
cells: the role in defence against disease. Science (Wash. DC).
214:24.
Trinchieri, G. 1990. Biology of natural killer cells. Adv. Im-
munol. In press.
Ciccone, E., O. Viale, D. Pende, M. Malnati, R. Biassoni, G.
Melioli, A. Moretta, E. O.Long, andL. Moretta.1988. Specific
lysis of allogeneic cells after activation of CD3- lymphocytes
in mixed lymphocyte culture. J. Exp. Med. 168:2403.
Ciccone, E., S. Ferrini, C. Bottino, O. Viale, I. Prigione, G.
Pantaleo, G. Tambussi, A. Moretta, and L. Moretta. 1988.
A monoclonal antibody specific for a common determinant
of the human T cell receptor gamma-directly activated
CD3*WT31- lymphocytes to express their functional pro-
gram(s).J. Exp. Med. 168:1.
Bottino, C., G. Tambussi, S. Ferrini, E. Ciccone, P. Varese,
M.C.Mingari, L. Moretta, andA. Moretta. 1988.Twosubsets
of human T lymphocytes expressing gamma/delta antigen
receptor identifiableby monoclonal antibodies directed twodis-
tinct molecular forms of the receptor.J. Exp Med. 168:491.
Moretta, A., G. Tambussi, E. Ciccone, D. Pende, G. Melioli,
and L. Moretta. 1990. CD16 surface molecules regulate the
cytolytic function of CD3-CD16* human "natural killer"
cells. Int. J. Cancer In press.
Moretta, A., D. Olive, A. Poggi, G. Pantaleo, C. Mawas, and
L. Moretta. 1986. Modulation of surface Tll molecules by
monoclonal antibodies: analysis of the functional relationship
between antigen-dependent andantigen-independent pathways
of human T cell activation. Eur. J. Immunol. 16:1427.
Ferrini, S., L. Moretta, G. Pantaleo, and A. Moretta. 1987.
Surface markersof human lymphokine-activated killer cells and





Specific Recognition of CD3-CD16* Natural Killer Cells
of these cells to specifically recognizeexogenous antigens (e.g.,
microbial structures) either in soluble form or in association
with cell surface molecules.
Int. J. Cancer. 39:18.
Biassoni, R., S. Ferrini, 1. Prigione, A. Moretta, and E. O.
Long. 1988. CD3-negativelymphokine-activated cytotoxiccells
express the CD3 epsilon-gene. J. Immunol. 140:1685.
Ceppellini, R., E. S. Curton, P. L. Mattiuz, V Miggiano, G.
Scudeller, and A. Serra. 1967. Genetics ofleukocyte antigens.
A family study of segregation andlinkage. In Histocompati-
bility Testing 1967. E. S. Curtoni, P. L. Mattiue, and R. M.
Tosi. editors. Munksgaard, Copenhagen. 149-156.
Harel-Bellan, A., A. Quillet, C. Marchiol, R. DeMars, T
Tursz, and D. Fradelizi. 1986. Natural killer susceptibility of
human cells may be regulated by genes in the HLA region
on chromosome 6. Proc Natl. Acad. Sci. USA. 83:5688.
Storkus, WJ., J. Alexander, J. A. Payne, J. R. Dawson, and
P. Cresswell. 1989. Reversal of natural killing susceptibility
in target cells expressing transfected class I HLA genes. Proc.
Natl. Acad. Sci. USA. 86:2361.
Cudkowicz, G., andM. Bennet. 1971. Peculiar immunobiolo-
gy of bone marrow allografts. I. Graftrejectionby heavily re-
sponder mice.J. Exp Med. 134:1513.
Rembecki, R. M., V Kumar, C. S. David, and M. Bennet.
1988. Bone marrow cell transplants involvingintra-H-2recom-
binant inbred mousestrains. Evidence that hemopoietic histo-
compatibility-1 (Hh-1) genes are distinct from H-213or H-2L.
J. Immunol. 141:2253.
Bennett, M. 1987. Biology and genetics of hybrid resistance.
Adv. Immunol. 41:333.
Sentman, C. L., J. Hackett, Jr, V Kumar, and M. Bennett.
1988. Identification of a subset of murine natural killer cells
that mediates rejectionof Hh-ldbut not Hh-lbbone marrow
grafts. J. Exp Med. 170:191.